✦ LIBER ✦

High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study

✍ Scribed by Ajay WANCHU; Bettadpura Shamanna SURYANARYANA; Shefali SHARMA; Aman SHARMA; Pradeep BAMBERY

Book ID: 118079624
Publisher: Wiley (Blackwell Publishing)
Year: 2009
Tongue: English
Weight: 113 KB
Volume: 12
Category: Article
ISSN: 1756-1841
DOI: 10.1111/j.1756-185x.2009.01417.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low‐dose intravenous cyclophosphamide in

Low‐dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease

✍ Valentini, G.; Paone, C.; La Montagna, G.; Chiarolanza, I.; Menegozzo, M.; Colut 📂 Article 📅 2006 🏛 Informa plc 🌐 English ⚖ 222 KB

Mycophenolate Versus Cyclophosphamide fo

Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study

✍ Panopoulos, Stylianos T.; Bournia, Vassiliki-Kalliopi; Trakada, Georgia; Giavri, 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 191 KB

Efficacy and safety of intravenous cyclo

Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up

✍ Akiko Tochimoto; Yasushi Kawaguchi; Masako Hara; Mutsuto Tateishi; Chikako Fukas 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 277 KB

Intermittent high-dose cyclophosphamide

Intermittent high-dose cyclophosphamide with and without prednisolone. A study of the relationships between toxicity, response and survival in metastatic lung cancer

✍ Nicholas Thatcher; John Wagstaff; Peter Wilkinson; Mike Palmer; Derek Crowther 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB

Serum Interleukin 6 Is Predictive of Ear

Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

✍ De Lauretis, A.; Sestini, P.; Pantelidis, P.; Hoyles, R.; Hansell, D. M.; Goh, N 📂 Article 📅 2013 🏛 Journal of Rheumatology Publishing Company 🌐 English ⚖ 637 KB

A one-year, phase I/IIa, open-label pilo

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease

✍ Dinesh Khanna; Rajeev Saggar; Maureen D. Mayes; Fereidoun Abtin; Philip J. Cleme 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views